Free Trial
NASDAQ:THTX

Theratechnologies (THTX) Stock Price, News & Analysis

Theratechnologies logo
$2.77 -0.15 (-5.14%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$2.75 -0.02 (-0.72%)
As of 05/2/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Theratechnologies Stock (NASDAQ:THTX)

Key Stats

Today's Range
$2.75
$2.95
50-Day Range
$1.33
$2.92
52-Week Range
$1.08
$3.13
Volume
429,229 shs
Average Volume
796,173 shs
Market Capitalization
$127.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Strong Buy

Company Overview

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

Receive THTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Theratechnologies and its competitors with MarketBeat's FREE daily newsletter.

THTX Stock News Headlines

The Man I Turn to In Times Like This
A storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when publisher Brett Aitken turns to Whitney Tilson—a man CNBC once dubbed “The Prophet.” Tilson just released a new prediction that runs counter to what mainstream finance is telling you.
Theratechnologies to further evaluate potential sale of the company
Theratechnologies Provides Update on Sale Process
Theratechnologies Provides Update on Sale Process
See More Headlines

THTX Stock Analysis - Frequently Asked Questions

Theratechnologies' stock was trading at $1.81 at the start of the year. Since then, THTX stock has increased by 53.0% and is now trading at $2.77.
View the best growth stocks for 2025 here
.

Theratechnologies Inc. (NASDAQ:THTX) announced its quarterly earnings results on Thursday, October, 10th. The company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.03 by $0.03. The company earned $22.60 million during the quarter.
Read the conference call transcript
.

Theratechnologies shares reverse split before market open on Monday, July 31st 2023. The 1-4 reverse split was announced on Monday, July 31st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 31st 2023. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

Theratechnologies subsidiaries include these companies: Katana, Pharma-G Inc., Theratechnologies Europe Inc., Theratechnologies Europe Limited, Theratechnologies Intercontinental Inc., and Theratechnologies U.S. Inc.

Top institutional shareholders of Theratechnologies include Cyndeo Wealth Partners LLC (0.06%).

Shares of THTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Theratechnologies investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), CymaBay Therapeutics (CBAY), Novo Nordisk A/S (NVO), Adobe (ADBE) and Celestica (CLS).

Company Calendar

Last Earnings
10/10/2024
Today
5/02/2025
Next Earnings (Estimated)
7/09/2025
Fiscal Year End
11/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:THTX
Employees
140
Year Founded
1993

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
277.00
P/E Growth
N/A
Net Income
$-23,960,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$88.67 million
Price / Cash Flow
N/A
Book Value
($0.45) per share
Price / Book
-6.16

Miscellaneous

Free Float
N/A
Market Cap
$127.36 million
Optionable
Optionable
Beta
1.11

Social Links

Free Today: Your Guide to Smarter Options Trades Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:THTX) was last updated on 5/3/2025 by MarketBeat.com Staff
From Our Partners